Nama's AI scorecard currently rates Indivior Pharmaceuticals Buy (7.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is INDV's P/E ratio?

Indivior Pharmaceuticals trades at a trailing price-to-earnings ratio of 8.5.

When does INDV report earnings?

Indivior Pharmaceuticals's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $1.22.

What is the INDV price target?

The median analyst price target from 4 analysts is $50.00, with a range of $45.00 – $53.00.

Is INDV Shariah compliant?

Nama's AAOIFI-style screen reads Indivior Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Indivior Pharmaceuticals (INDV)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

Indivior Pharmaceuticals (INDV) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $4.28B, a trailing price-to-earnings ratio of 8.5 and a free-cash-flow yield of -2.0%. Over the most recent reported fiscal year, revenue grew 4.3% and free cash flow per share fell 2042.5%. Nama's AI scorecard rates it Buy, 7.0 out of 10.

AI scorecard

Buy · 7.0/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-15.2%

How far the last close sits under the highest price of the past five years.

Market cap	$4.28B
Trailing P/E	8.5
Price / book	—
Price / sales	3.1
FCF yield	-2.0%
Dividend yield	—
Gross margin	82.0%
Operating margin	31.8%
Net margin	26.6%
Revenue growth (YoY)	+4.3%
Revenue growth (3-yr annual)	+11.2%
EPS growth (YoY)	+47.3%
FCF/share growth (YoY)	-2042.5%
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

INDV earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $1.22). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$1.32	$1.13	+16.8%	$356.00M
Q2 2026	Aug 3, 2026	$1.15	$0.92	+25.0%	$343.00M
Q1 2026	Apr 30, 2026	$0.96	$0.66	+45.5%	$317.00M
Q4 2025	Feb 26, 2026	$0.82	$0.67	+22.4%	$358.00M

INDV analyst price target

Median target $50.00 from 4 analysts, ranging $45.00 – $53.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live INDV data on Nama Insights →

INDV FAQ

Is INDV a buy?: Nama's AI scorecard currently rates Indivior Pharmaceuticals Buy (7.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is INDV's P/E ratio?: Indivior Pharmaceuticals trades at a trailing price-to-earnings ratio of 8.5.
When does INDV report earnings?: Indivior Pharmaceuticals's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $1.22.
What is the INDV price target?: The median analyst price target from 4 analysts is $50.00, with a range of $45.00 – $53.00.
Is INDV Shariah compliant?: Nama's AAOIFI-style screen reads Indivior Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.